Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce we are in final negotiations to purchase 50% of a 10,000 square foot Cancer Centre in Arizona. This Cancer Centre already has 500 existing patients with new patients inquiring daily, from around the world, looking for cannabis-based treatments for numerous critical ailments.
Cannabis Science expects to sign the deal for the Cancer Centre within the next few days. We will release detailed information regarding purchase to our shareholders and the general public. First and foremost, Cannabis Science is a patient orientated company. This acquisition will expand our patient support. With our on site oncologist and radiologist, we will medically document patient outcomes.
The 10,000 square foot building features 20 clinic rooms for those new and existing patients. There will be an onsite physician to guide them and suggest the appropriate treatment package. This Cancer Centre is equipped to operate as a full service medical cannabis treatment center, including a lab for clinical testing. Incoming patients will first get an assessment and when necessary, an x-ray or MRI. There will also be a separate specialized doctor on site, who can issue an MMC card to incoming patients who do not already have one. Additionally, as part of this joint venture, Cannabis Science will have associated local dispensaries and labs for testing.
This Cancer Centre will allow new and existing patients to seek professional help and assistance, while assisting patients to self-administer treatments for different ailments including: AIDS, Alzheimers, Anti-Aging, Autism, Asthma, Arthritis, Auto Immune Disease, Brain Trauma (Closed Head Injury), Cancer, Chronic Pain Management, Crohn’s, Irritable Bowel Syndrome (IBS), Diabetes, Digestive Illnesses, Gastro Intestinal Reflux Disease (GERD), Glaucoma, High Blood Pressure, Influenza, Methicillin-Resistant Staphylococcus Aureus (MRSA), Multiple Sclerosis (MS), Post Traumatic Stress Disorder (PTSD) and Tourette Syndrome.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.Business Wire
Last updated on: 19/04/2012